The mid-size pharmaceutical market in Asia Pacific is expected to grow from US$ 131,119.99 million in 2022 to US$ 196,114.51 million by 2028; it is estimated to grow at a CAGR of 6.9% from 2022 to 2028.
Over the last decade, the pharmaceutical industry has witnessed many transformational trends and innovations that will improve the medicines available to patients around the region. In just ten years, the influence of artificial intelligence and big data on diagnosing and treating diseases and a shift toward preventing life-threatening conditions rather than medicating them lead to evolution of healthcare. With the evolution of recent technologies, new entrants initiate several health start-ups. For instance, Christopher Benoit, an expert in enzyme development and production, founded Alpha zyme in 2018. In October 2020, Alp zyme partnered with Qualio to facilitate the company’s growth.
Unlike large pharmaceutical companies, medium-sized pharmaceutical companies are usually not constrained by huge overheads and bureaucracy. However, these companies have focus on specific areas of drug development. In recent years, partnerships between the pharmaceutical and digital health companies have increased significantly. These commercial deployment deals are aimed at digitally-enabled pharmaceutical products, creating new companies, or multibillion-dollar acquisitions. Thus, pharma companies are a growing part of the digital health boom. Therefore, the rising number of healthcare start-ups is expected to offer lucrative growth opportunities for the growth of the Asia Pacific mid-size pharmaceutical market in the coming years.
By introducing new features and technologies, vendors in the Asia Pacific mid-size pharmaceutical market can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the market growth at a good CAGR during the forecast period.
Over the last decade, the pharmaceutical industry has witnessed many transformational trends and innovations that will improve the medicines available to patients around the region. In just ten years, the influence of artificial intelligence and big data on diagnosing and treating diseases and a shift toward preventing life-threatening conditions rather than medicating them lead to evolution of healthcare. With the evolution of recent technologies, new entrants initiate several health start-ups. For instance, Christopher Benoit, an expert in enzyme development and production, founded Alpha zyme in 2018. In October 2020, Alp zyme partnered with Qualio to facilitate the company’s growth.
Unlike large pharmaceutical companies, medium-sized pharmaceutical companies are usually not constrained by huge overheads and bureaucracy. However, these companies have focus on specific areas of drug development. In recent years, partnerships between the pharmaceutical and digital health companies have increased significantly. These commercial deployment deals are aimed at digitally-enabled pharmaceutical products, creating new companies, or multibillion-dollar acquisitions. Thus, pharma companies are a growing part of the digital health boom. Therefore, the rising number of healthcare start-ups is expected to offer lucrative growth opportunities for the growth of the Asia Pacific mid-size pharmaceutical market in the coming years.
By introducing new features and technologies, vendors in the Asia Pacific mid-size pharmaceutical market can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the market growth at a good CAGR during the forecast period.
Asia Pacific Mid-Size Pharmaceutical Market Segmentation
The Asia Pacific mid-size pharmaceutical market is segmented on the basis of type, drug development type, formulation, therapy class, and country.- Based on type, the Asia Pacific mid-size pharmaceutical market is bifurcated into prescription and over-the-counter. In 2022, the over-the-counter segment accounted for a larger market share.
- Based on drug development type, the market is bifurcated into in-house and outsource. The outsource segment held a larger market share in 2022.
- Based on formulation, the Asia Pacific mid-size pharmaceutical market is segmented into tablets and capsules, injectables, sprays, and other formulations. The tablets & capsules segment held the largest market share in 2022.
- Based on therapy class, the market is segmented into cardiovascular diseases, pain management, diabetes, cancer, and other conditions. The diabetes segment held the largest market share in 2022.
- Based on country, the Asia Pacific mid-size pharmaceutical market is segmented into Australia, China, India, Japan, South Korea, and Rest of Asia Pacific. China held the largest market share in 2022.
Table of Contents
1. Introduction
3. Research Methodology
4. APAC Mid-Size Pharmaceutical - Market Landscape
5. Mid-Size Pharmaceutical Market - Key Market Dynamics
6. Mid-Size Pharmaceutical Market- APAC Analysis
7. APAC Mid-Size Pharmaceutical Market Revenue and Forecasts To 2028- by Type
8. APAC Mid-Size Pharmaceutical Market Analysis - By Drug Development Type
9. APAC Mid-Size Pharmaceutical Market - By Formulation
10. APAC Mid-Size Pharmaceutical Market - By Therapy Class
11. APAC Mid-Size Pharmaceutical Market Revenue and Forecasts to 2028 - Country Analysis
12. Mid-Size Pharmaceutical Market-Industry Landscape
13. Company Profiles
14. Appendix
Companies Mentioned
- Alexion Pharmaceuticals, Inc.
- Bausch Health Companies Inc.
- Daiichi Sankyo Company Limited
- Eisai Co., Ltd.
- Endo Pharmaceuticals Inc.
- Mallinckrodt
- Regeneron Pharmaceuticals, Inc
- Sun Pharmaceutical Industries Ltd
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 146 |
| Published | September 2022 |
| Forecast Period | 2022 - 2028 |
| Estimated Market Value ( USD | $ 131119.99 Million |
| Forecasted Market Value ( USD | $ 196114.51 Million |
| Compound Annual Growth Rate | 6.9% |
| Regions Covered | Asia Pacific |
| No. of Companies Mentioned | 8 |
